Cancel anytime
Abbott Laboratories (ABT)ABT
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/28/2024: ABT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -4.72% | Upturn Advisory Performance 3 | Avg. Invested days: 35 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/28/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -4.72% | Avg. Invested days: 35 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/28/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 203.59B USD |
Price to earnings Ratio 34.72 | 1Y Target Price 129.76 |
Dividends yield (FY) 1.93% | Basic EPS (TTM) 3.29 |
Volume (30-day avg) 5132661 | Beta 0.72 |
52 Weeks Range 90.62 - 119.85 | Updated Date 10/27/2024 |
Company Size Large-Cap Stock | Market Capitalization 203.59B USD | Price to earnings Ratio 34.72 | 1Y Target Price 129.76 |
Dividends yield (FY) 1.93% | Basic EPS (TTM) 3.29 | Volume (30-day avg) 5132661 | Beta 0.72 |
52 Weeks Range 90.62 - 119.85 | Updated Date 10/27/2024 |
Earnings Date
Report Date 2024-10-16 | When BeforeMarket |
Estimate 1.2 | Actual 1.21 |
Report Date 2024-10-16 | When BeforeMarket | Estimate 1.2 | Actual 1.21 |
Profitability
Profit Margin 13.99% | Operating Margin (TTM) 17.55% |
Management Effectiveness
Return on Assets (TTM) 6.26% | Return on Equity (TTM) 14.44% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 34.72 | Forward PE 22.17 |
Enterprise Value 206599110656 | Price to Sales(TTM) 4.94 |
Enterprise Value to Revenue 5 | Enterprise Value to EBITDA 22.92 |
Shares Outstanding 1739900032 | Shares Floating 1728901575 |
Percent Insiders 0.53 | Percent Institutions 79.63 |
Trailing PE 34.72 | Forward PE 22.17 | Enterprise Value 206599110656 | Price to Sales(TTM) 4.94 |
Enterprise Value to Revenue 5 | Enterprise Value to EBITDA 22.92 | Shares Outstanding 1739900032 | Shares Floating 1728901575 |
Percent Insiders 0.53 | Percent Institutions 79.63 |
Analyst Ratings
Rating 4.19 | Target Price 110.65 | Buy 7 |
Strong Buy 13 | Hold 6 | Sell 1 |
Strong Sell - |
Rating 4.19 | Target Price 110.65 | Buy 7 | Strong Buy 13 |
Hold 6 | Sell 1 | Strong Sell - |
AI Summarization
Abbott Laboratories: A Comprehensive Overview
Company Profile
History and Background:
Abbott Laboratories, founded in 1888, is a global healthcare company headquartered in Illinois, USA. It has evolved from a small alkaloid manufacturer to a diversified leader in diagnostics, medical devices, and nutritional products. Notable milestones include the development of the first commercially available penicillin in the 1940s and the creation of the world's first rapid HIV test in the 1980s.
Core Business Areas:
Abbott operates in four segments:
- Diagnostics: Delivers tests and instruments for diagnosing various diseases and monitoring health conditions.
- Medical Devices: Offers a range of products for cardiovascular, diabetes, neuromodulation, and other medical fields.
- Nutrition: Provides nutritional products for infants, children, and adults with specific dietary needs.
- Established Pharmaceuticals: Offersbranded generic pharmaceuticals and over-the-counter medicines.
Leadership Team and Corporate Structure:
Robert B. Ford serves as President and CEO. The leadership team comprises experienced executives with expertise in various healthcare fields. Abbott follows a decentralized structure, empowering each business unit with decision-making authority.
Top Products and Market Share:
- Top Products: FreeStyle Libre (continuous glucose monitoring system), MitraClip (transcatheter mitral valve repair system), Similac (infant formula), and BinaxNOW (COVID-19 antigen tests).
- Market Share: Abbott holds leading positions in several segments:
- Global leader in rapid diagnostics.
- Strong presence in diabetes care, with FreeStyle Libre holding a significant market share.
- Leading player in the adult nutrition market.
- Product Performance: Abbott's products are generally well-received, with FreeStyle Libre and MitraClip garnering high patient satisfaction and positive clinical outcomes.
Total Addressable Market:
The global healthcare market is vast, estimated at over $10 trillion in 2023. Abbott operates in several segments within this market, including diagnostics ($65 billion), medical devices ($450 billion), and nutrition (~$350 billion).
Financial Performance:
- Revenue: Abbott's revenue has grown steadily in recent years, reaching $43.1 billion in 2022.
- Net Income: Net income has also grown, reaching $7.9 billion in 2022.
- Profit Margins: Profit margins are healthy, with a gross margin of 58.5% and an operating margin of 25.1% in 2022.
- Earnings per Share (EPS): EPS has increased consistently, reaching $3.21 in 2022.
- Cash Flow: Abbott generates strong cash flow, with operating cash flow exceeding $9 billion in 2022.
- Balance Sheet: The company maintains a healthy balance sheet with moderate debt levels.
Dividends and Shareholder Returns:
- Dividend History: Abbott has a long history of dividend payments, with a current annual dividend of $0.48 per share. The dividend yield is approximately 1.6%.
- Shareholder Returns: Over the past 5 years, Abbott has delivered total shareholder returns of over 80%.
Growth Trajectory:
- Historical Growth: Abbott has experienced consistent growth over the past 5-10 years, driven by strong product launches and market share gains.
- Future Growth Projections: Analysts expect Abbott to continue growing its earnings at a mid-single-digit rate in the coming years.
- Recent Growth Initiatives: Abbott is actively pursuing growth through product innovation, strategic acquisitions, and expansion into new markets.
Market Dynamics:
The healthcare industry is characterized by technological advancements, evolving regulatory landscapes, and increasing demand for cost-effective solutions. Abbott is well-positioned to capitalize on these trends through its innovative products and focus on value-based care.
Competitors:
- Diagnostics: Danaher (DHR), Thermo Fisher Scientific (TMO), Siemens Healthineers (SHL).
- Medical Devices: Medtronic (MDT), Boston Scientific (BSX), Johnson & Johnson (JNJ).
- Nutrition: Nestle (NSRGY), Danone (DANOY), Reckitt Benckiser (RKT).
Potential Challenges and Opportunities:
- Challenges: Supply chain disruptions, pricing pressures, and competition from generic drug manufacturers.
- Opportunities: Expansion into emerging markets, new product launches in high-growth areas, and partnerships with technology companies.
Recent Acquisitions (2020-2023):
- Trianon Acquisition (2023): Acquired Trianon, a medical device company specialized in vascular closure devices, for $1.6 billion. This acquisition strengthens Abbott's position in the interventional cardiology market.
- Cardiovascular Systems Acquisition (2022): Acquired Cardiovascular Systems, a company developing and commercializing interventional products for peripheral artery disease, for $1.1 billion. This acquisition adds innovative technologies to Abbott's vascular portfolio.
- Neuraptive Acquisition (2021): Acquired Neuraptive, a company developing non-invasive neurostimulation therapies for epilepsy, for $140 million. This acquisition expands Abbott's neurology portfolio and reinforces its commitment to offering innovative solutions for neurological disorders.
AI-Based Fundamental Rating:
Based on an AI-based analysis, Abbott Laboratories receives a fundamental rating of 8 out of 10. This rating is driven by the company's strong financial performance, leading market positions, and promising growth prospects. However, potential challenges such as supply chain issues and competition need to be considered.
Sources and Disclaimers:
This analysis utilizes data from Abbott Laboratories' annual reports, SEC filings, company presentations, and industry reports. The information provided should not be considered financial advice.
Disclaimer:
This information is for educational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Abbott Laboratories
Exchange | NYSE | Headquaters | North Chicago, IL, United States |
IPO Launch date | 1978-01-13 | Chairman of the Board, President & CEO | Mr. Robert B. Ford |
Sector | Healthcare | Website | https://www.abbott.com |
Industry | Medical Devices | Full time employees | 114000 |
Headquaters | North Chicago, IL, United States | ||
Chairman of the Board, President & CEO | Mr. Robert B. Ford | ||
Website | https://www.abbott.com | ||
Website | https://www.abbott.com | ||
Full time employees | 114000 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.